Close Menu

NEW YORK – Sonic Healthcare USA said on Tuesday it has expanded its license for the ThyroSeq Genomic Classifier, signing a new 15-year exclusive agreement with the University of Pittsburgh Medical Center, the test's developer.

Under the expanded agreement, the test, which aids in the management of thyroid nodules of indeterminate cytology, will become available through all of Sonic's clinical labs and anatomic pathology practices in the US. Previously, the company has offered the test only through its CBLPath division.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.